$AZN AstraZeneca’s $2B investment in $SMMT Summit Therapeutics has me watching ivonescimab more closely. I’m curious whether pairing it with an antibody drug conjugate can improve cancer treatment and how much added toxicity comes with that benefit.
Next date to watch is November 14, when the FDA decides on this drug for lung cancer. However, This is a major amendment, which under FDA rules can trigger a three month extension of the review clock, pushing the decision to roughly mid-February 2027.
1
1
325
Eli Lilly became the first drug company to reach a $1 trillion valuation.
But maintaining that lead may depend on what comes after Mounjaro and Zepbound.
Today, $LLY reported that its diabetes pill Foundayo produced greater weight loss and larger A1C reductions than Novo Nordisk’s 25 mg oral semaglutide.
But there is an important caveat:
The two medicines were never tested against each other in the same clinical trial.
Lilly compared results from two separate late-stage studies using statistical methods an indirect treatment comparison.
That makes the finding interesting, but not the same as evidence from a randomized head-to-head trial.
Update from today: Lilly reported that Foundayo showed 1.5–2.4 percentage points greater weight loss and 0.3–0.6 points larger A1C reductions than Novo Nordisk’s 25 mg oral semaglutide.
1
192
This video was recorded on June 12, 2026. Here’s the latest update: $GRAL rallied 35% after FDA reviewers raised no major concerns about Galleri’s accuracy or safety. The advisory committee meets Wednesday, the next major step toward a potential FDA approval decision.
477
Seven biotech developments: approvals, Phase 3 misses, clinical holds, acquisitions and cell therapy.
One recurring lesson:
A strong mechanism can get a drug into clinical trials. Only meaningful patient outcomes can carry it through.
the summary of last week’s biotech update . $NOVN. $NOVO.NE $BAYRY $ABVX $LLY
126
Today, before speaking about progress, we remember the nearly 3,000 lives lost on September 11, 2001 the families forever changed, the first responders who ran toward danger, and the communities that continue to carry this loss.
Twenty five years have passed, and science has transformed in ways that would have been difficult to imagine then.
In 2001, scientists had only recently published the first draft of the human genome. Today, we can sequence genomes rapidly, identify disease causing mutations, and edit DNA itself.
We have watched mRNA move from a fragile laboratory molecule to a vaccine platform used around the world.
We have learned to re-engineer a patient’s own immune cells through CAR-T therapy to recognize certain cancers.
We have seen the first CRISPR based medicine approved, turning gene editing from a laboratory possibility into a treatment for patients.
Artificial intelligence can now help predict protein structures, identify potential drug candidates, and change how researchers approach biological questions.
Science has moved remarkably far.
Yet days like today remind us that progress is not measured only by what humanity can discover. It is also measured by how we use knowledge with compassion, responsibility, and a commitment to protecting human life.
Today, we remember those who were lost and honor the people whose courage, service, and humanity endured.
1
173
Last night, 2,977 lights illuminated the harbor one for every life lost on September 11 rising together to form the silhouette of the Twin Towers.
A reminder that behind every number was a person, a family, and a future forever changed. #newyork #september #TwinTowers
139
Pfizer and Valneva’s Phase 3 VLA15 trial is testing a clever idea: create OspA antibodies that enter a feeding tick and target Lyme bacteria before they reach humans.
The trial showed meaningful protection but narrowly missed its primary statistical bar. It has completed two pivotal Phase 3 trials and is now under EMA review. $VALN
151
Autoimmune disease isn’t always driven by one broken pathway it can be two immune pathways sustaining the same disease.
Zura Bio’s tibulizumab targets IL-17A driven inflammation and BAFF supported B-cell survival simultaneously.
Compelling biology. Now Phase 2 has to prove it. $ZURA
3
232
Hiking around Peggy’s Cove, with no one around, I kept noticing life everywhere.
Plants growing between rocks. Fungi surviving on surfaces that looked almost barren. Tiny creatures along the shore.
And somehow, my mind kept coming back to the same thing:
the cell.
Something so small, yet capable of sensing its environment, communicating, producing energy, repairing damage, dividing, adapting and coordinating thousands of processes at once.
I’ve spent years studying biology, and somehow the more I understand it, the more incredible it becomes.
Standing there, surrounded by life in its simplest forms, I couldn’t stop thinking:
How did God design something this intricate?
We have mapped genomes, identified pathways, watched molecules move inside cells and yet there is still so much about a single cell that we don’t fully understand.
Maybe that’s one of my favorite things about science.
The more you learn about life, the more there is to be in awe of🧬🌿🌺
1
200
$CUE is becoming an interesting immunology catalyst story.
Cue Biopharma is exploring two sides of immune control:
→ IgE in allergy
→ Treg biology through IL-2 + TGF-β signaling in autoimmunity
Its 145-patient Phase 2 trial in chronic spontaneous urticaria is expected to read out by the end of Q3 2026 with omalizumab as an active comparator.
1
491




